NASHVILLE – Cumberland Emerging Technologies, Inc. (CET) announced today the addition of Lindsey Cox to its board of directors. CET works to develop innovative new biomedical products emerging from university-based research, and also manages Nashville’s Life Sciences Center – which supports a growing number of biomedical startups and successful graduates.

Cox is the CEO of Launch Tennessee (LaunchTN), a public-private partnership working to make Tennessee the most startup-friendly state in the nation. LaunchTN provides resources to entrepreneurs, mentorship, accelerators, entrepreneurship training and capital access.

“Lindsey brings to our board valuable experience in supporting entrepreneurial endeavors. This is obviously a key perspective in an innovation-focused organization like CET and we are excited to welcome her to the board,” said A.J. Kazimi, CEO of CET and Cumberland Pharmaceuticals.

Cox previously spent six years at LaunchTN prior to rejoining joining the organization as CEO in April 2022. She previously served as LaunchTN’s finance, accounting and compliance manager, innovation manager, director of its 3686 Entrepreneurship Festival, and director of operations and government affairs. After leaving LaunchTN in 2019, she worked at the office of innovation and entrepreneurship at the Economic Development Administration – a bureau of the U.S. Department of Commerce, and then at CO.LAB – the Chattanooga entrepreneur center, as their CEO.

Cox earned both her master’s degree and a bachelor’s degree in accounting from Tennessee Tech University.

CET’s board of directors also includes Alan R. Bentley, assistant vice chancellor of technology transfer at Vanderbilt University; Kenneth J. Holroyd, vice president of technology transfer at Vanderbilt University Medical Center; Wei Wang (Jack), CEO of WinHealth Pharmaceuticals; Samuel M. Lawrence, CEO and co-founder of CytoViva, Inc. and Joseph O. Rolwing, senior director at CET, where he manages Nashville’s Life Sciences Center.

Cumberland Emerging Technologies, Inc. (www.cet-fund.com) is a joint initiative among Cumberland Pharmaceuticals Inc., Vanderbilt University, Launch Tennessee and WinHealth Pharma.

The mission of CET is to bring biomedical technologies and products conceived at Vanderbilt and other regional research centers to the marketplace.

CET helps manage the development and commercialization process for select projects and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products.

CET’s Life Sciences Center, located in Nashville, Tennessee, provides laboratory space, equipment and infrastructure to early-stage life sciences companies.